A Phase 3 interventional study of Teduglutide in Short Bowel Syndrome, sponsored by Takeda. Completed at 6 sites in Japan. Open to participants aged 4 Months and older. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 20th largest by enrollment, is the only one that started in 2022, is one of 16 in phase 3, and was the 18th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 4 mo–17 yrs
By country, each count listing its studies:
teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 4 Months and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2022.
This study's enrollment of 3 is below the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 20 across the 20 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 6 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
26 studies in Short Bowel Syndrome by Takeda: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 16 (70%) have results posted.
Among the 26 studies in Short Bowel Syndrome by Takeda, this one is the 18th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2022, is one of 17 in phase 3, and was the 21st registered.
Takeda’s Short Bowel Syndrome studies by the year they started, since 2004.
1 of the studies testing teduglutide in Short Bowel Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973304Phase 3TakedaA Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | 2027-02-10 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Short Bowel Syndrome:
This tab as a report to print or save as PDF → With an account.
The main aims of the study are to check for side effects from teduglutide.
Participants will receive a daily injection of teduglutide just under the skin (subcutaneous) for 24 weeks. Then they are followed up for another 4 weeks. Participants may be able to repeat this treatment if they meet specific criteria. The study doctors will check for side effects from teduglutide until it becomes commercially available. The maximum duration of treatment is approximately 51.3 weeks.
A study of teduglutide in Japanese children with short bowel syndrome aged 4 months or older.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Signs of active, severe, or unstable clinically significant hepatic impairment during the screening period as meeting at least 2 of any of the following parameters:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive teduglutide 0.05 milligram per kilogram \[mg/kg\] (0.025 mg/kg for participants with moderate or greater renal impairment) subcutaneous \[SC\] injection once daily in a 28-week treatment cycle consisting of a 24-week treatment period followed by a 4-week no treatment follow-up period for a maximum of 3 cycles.
Drug: Teduglutide
Teduglutide 0.05 mg/kg SC injection
Also known as: TAK-633
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as any AEs whose onset occurred, severity worsened, or intensity increased after receiving the investigational product.
Time frame: From first dose of study drug until follow-up visit (4 weeks after end of treatment [EOT]/end of termination [ET] {up to 47.3-51.3 weeks})
Number of Participants With Serious Adverse Events (SAEs)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence that at any dose: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly /birth defect, is the other important medical event.
Time frame: From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])
Number of Participants With Adverse Events of Special Interest (AESIs)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AESI, whether serious or non-serious, is one of scientific and medical concern specific to the compound or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor may be appropriate.
Time frame: From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])
Number of Participants With Clinically Significant Abnormalities in Vital Signs Reported as an Adverse Event
Vital signs include systolic and diastolic blood pressure, heart rate and body temperature.
Time frame: From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])
Change From Baseline in Body Weight Z-Score at EOT
A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to WHO Child Growth Standards used for assessment of this outcome measure, a weight for age Z-score below -2 indicates underweight.
Time frame: Baseline, EOT (up to 47.3-51.3 weeks)
Change From Baseline in Height Z-Score at EOT
A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to WHO Child Growth Standards used for assessment of this outcome measure, a height for age Z-score below -2 indicates stunted.
Time frame: Baseline, EOT (up to 47.3-51.3 weeks)
Change From Baseline in Head Circumference Z-Score at EOT
A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to the Food and Nutrition Technical Assistance (FANTA) Guide to Anthropometry used for assessment of this outcome measure, a head circumference for age Z-score below -2 indicates small head circumference.
Time frame: Baseline, EOT (up to 47.3-51.3 weeks)
Change From Baseline in Weight-for-Length Z-Score at EOT
A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to WHO Child Growth Standards used for assessment of this outcome measure, a weight for length Z-score below -2 indicates wasted (recent and severe weight loss).
Time frame: Baseline, EOT (up to 47.3-51.3 weeks)
Number of Participants With Any Laboratory Safety Finding Reported as an Adverse Event
Laboratory safety parameters included biochemistry, hematology, and urinalysis.
Time frame: From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])
Number of Participants With a Change in Urine Output Reported as an Adverse Event
Urine and stool output was recorded and calculated in the output diary over a 48-hour period of parenteral support (PS) and enteral nutrition (EN) stability before every site visit and within 1 week of implementing a change in the PS prescription.
Time frame: From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])
Number of Participants With a Change in Stool Output Reported as an Adverse Event
Urine and stool output was recorded and calculated in the output diary over a 48-hour period of PS and EN stability before every site visit and within 1 week of implementing a change in the PS prescription.
Time frame: From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])
Change From Baseline in PS Volume
PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume and calories during the treatment period. An end of treatment (EOT) was defined as the last determination of endpoint of the last cycle.
Time frame: Baseline, Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2: Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT and overall EOT (for up to 47.3-51.3 weeks) [cycle length=28 weeks]
Percent Change From Baseline in PS Volume
Percent change from baseline in PS volume was calculated as follows; (PS volume at each point \[Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT\] - PS volume at baseline)/ PS volume at baseline \*100 (percent). PS (parenteral nutrition or intravenous fluids) was to be considered for managing nutritional support in terms of volume and calories during the treatment period. An EOT was defined as the last determination of endpoint of the last cycle.
Time frame: Baseline, Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2 = Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT and overall EOT (for up to 47.3-51.3 weeks) [cycle length=28 weeks]
Number of Participants Who Demonstrate at Least 20 Percent (%) Reduction From Baseline in PS Volume
PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume and calories during the treatment period. An EOT was defined as the last determination of endpoint of the last cycle.
Time frame: Baseline, Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2 = Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT and overall EOT (for up to 47.3-51.3 weeks) [cycle length=28 weeks]
Number of Participants Who Achieved Enteral Autonomy
Achieving enteral autonomy is defined as complete weaning off PS. PS (parenteral nutrition or intravenous fluids) was to be considered for managing nutritional support in terms of volume and calories during the treatment period.
Time frame: Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2 = Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT and overall EOT (for up to 47.3-51.3 weeks) [cycle length=28 weeks]
Change From Baseline in Number of Days Per Week of PS Usage at EOT
PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume and calories during the treatment period.
Time frame: Baseline, Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2 = Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT, and overall EOT (for 47.3-51.3 weeks) [cycle length=28 weeks]
Three participants took part in the study at six investigative sites in Japan from 4 January 2022 to 27 September 2023.
| Milestone | Teduglutide |
|---|---|
| Started | 3 |
| Completed | 3 |
| Not completed | 0 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as any AEs whose onset occurred, severity worsened, or intensity increased after receiving the investigational product.
| Participants | Teduglutide |
|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 3 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence that at any dose: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly /birth defect, is the other important medical event.
| Participants | Teduglutide |
|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 3 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AESI, whether serious or non-serious, is one of scientific and medical concern specific to the compound or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor may be appropriate.
| Participants | Teduglutide |
|---|---|
| Number of Participants With Adverse Events of Special Interest (AESIs) | 0 |
Vital signs include systolic and diastolic blood pressure, heart rate and body temperature.
| Participants | Teduglutide |
|---|---|
| Number of Participants With Clinically Significant Abnormalities in Vital Signs Reported as an Adverse Event | 0 |
A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to WHO Child Growth Standards used for assessment of this outcome measure, a weight for age Z-score below -2 indicates underweight.
| Z score | Teduglutide |
|---|---|
| Change From Baseline in Body Weight Z-Score at EOT | 1.637 ± 2.8839 |
A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to WHO Child Growth Standards used for assessment of this outcome measure, a height for age Z-score below -2 indicates stunted.
| Z score | Teduglutide |
|---|---|
| Change From Baseline in Height Z-Score at EOT | 0.590 ± 1.9949 |
A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to the Food and Nutrition Technical Assistance (FANTA) Guide to Anthropometry used for assessment of this outcome measure, a head circumference for age Z-score below -2 indicates small head circumference.
| Z score | Teduglutide |
|---|---|
| Change From Baseline in Head Circumference Z-Score at EOT | 1.130 ± 0.4101 |
A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to WHO Child Growth Standards used for assessment of this outcome measure, a weight for length Z-score below -2 indicates wasted (recent and severe weight loss).
| Z score | Teduglutide |
|---|---|
| Change From Baseline in Weight-for-Length Z-Score at EOT | 4.240 ± NA |
Laboratory safety parameters included biochemistry, hematology, and urinalysis.
| Participants | Teduglutide |
|---|---|
| Number of Participants With Any Laboratory Safety Finding Reported as an Adverse Event | 1 |
Urine and stool output was recorded and calculated in the output diary over a 48-hour period of parenteral support (PS) and enteral nutrition (EN) stability before every site visit and within 1 week of implementing a change in the PS prescription.
| Participants | Teduglutide |
|---|---|
| Number of Participants With a Change in Urine Output Reported as an Adverse Event | 1 |
Urine and stool output was recorded and calculated in the output diary over a 48-hour period of PS and EN stability before every site visit and within 1 week of implementing a change in the PS prescription.
| Participants | Teduglutide |
|---|---|
| Number of Participants With a Change in Stool Output Reported as an Adverse Event | 0 |
PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume and calories during the treatment period. An end of treatment (EOT) was defined as the last determination of endpoint of the last cycle.
| milliliters per kilograms (mL/kg)/day | Teduglutide |
|---|---|
| Cycle 1, Week 1 | 3.13 ± 10.041 |
| Cycle 1, Week 2 | 7.82 ± 19.334 |
| Cycle 1, Week 4 | -1.31 ± 6.491 |
| Cycle 1, Week 8 | 10.27 ± 13.788 |
| Cycle 1, Week 12 | 5.83 ± 15.979 |
| Cycle 1, Week 16 | 1.89 ± 16.386 |
| Cycle 1, Week 20 | 1.82 ± 6.673 |
| Cycle 1, Week 24 | 0.66 ± 9.511 |
| Cycle 1, EOT | 0.66 ± 9.511 |
| Cycle 2, Week 0 | -0.07 ± 12.808 |
| Cycle 2 Week 1 | 0.11 ± 15.080 |
| Cycle 2, Week 2 | -2.32 ± 13.465 |
| Cycle 2, Week 4 | -0.71 ± 12.202 |
| Cycle 2, Week 8 | -4.81 ± 13.214 |
| Cycle 2, Week 12 | -8.42 ± 11.909 |
| Cycle 2, Week 16 | -10.14 ± 10.452 |
| Cycle 2, Week 20 | -8.20 ± 0.509 |
| Cycle 2, Week 24 | -9.28 ± 2.092 |
| Cycle 2, EOT | -9.11 ± 1.508 |
| Cycle 3, Week 0 | -12.86 ± NA |
| Cycle 3, Week 1 | -13.67 ± NA |
| Cycle 3, Week 2 | -5.04 ± NA |
| Cycle 3, EOT | -5.04 ± NA |
| Overall EOT | -10.99 ± 27.093 |
Percent change from baseline in PS volume was calculated as follows; (PS volume at each point \[Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT\] - PS volume at baseline)/ PS volume at baseline \*100 (percent). PS (parenteral nutrition or intravenous fluids) was to be considered for managing nutritional support in terms of volume and calories during the treatment period. An EOT was defined as the last determination of endpoint of the last cycle.
| percent change | Teduglutide |
|---|---|
| Cycle 1, Week 1 | 4.82 ± 13.391 |
| Cycle 1, Week 2 | 11.27 ± 26.175 |
| Cycle 1, Week 4 | -1.51 ± 8.881 |
| Cycle 1, Week 8 | 13.48 ± 19.471 |
| Cycle 1, Week 12 | 6.97 ± 22.006 |
| Cycle 1, Week 16 | 1.61 ± 22.136 |
| Cycle 1, Week 20 | 2.94 ± 8.794 |
| Cycle 1, Week 24 | 1.24 ± 12.938 |
| Cycle 1, EOT | 1.24 ± 12.938 |
| Cycle 2, Week 0 | 0.07 ± 17.520 |
| Cycle 2, Week 1 | 0.26 ± 20.634 |
| Cycle 2, Week 2 | -2.81 ± 18.432 |
| Cycle 2, Week 4 | -0.62 ± 16.671 |
| Cycle 2, Week 8 | -6.00 ± 18.175 |
| Cycle 2, Week 12 | -10.21 ± 16.645 |
| Cycle 2, Week 16 | -13.03 ± 14.937 |
| Cycle 2, Week 20 | -9.73 ± 3.073 |
| Cycle 2, Week 24 | -10.50 ± 6.059 |
| Cycle 2, EOT | -10.98 ± 4.363 |
| Cycle 3, Week 0 | -17.69 ± NA |
| Cycle 3, Week 1 | -18.79 ± NA |
| Cycle 3, Week 2 | -6.93 ± NA |
| Cycle 3, EOT | -6.93 ± NA |
| Overall EOT | -13.13 ± 37.259 |
PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume and calories during the treatment period. An EOT was defined as the last determination of endpoint of the last cycle.
| Participants | Teduglutide |
|---|---|
| Cycle 1, Week 1 | 0 |
| Cycle 1, Week 2 | 0 |
| Cycle 1, Week 4 | 0 |
| Cycle 1, Week 8 | 0 |
| Cycle 1, Week 12 | 0 |
| Cycle 1, Week 16 | 1 |
| Cycle 1, Week 20 | 0 |
| Cycle 1, Week 24 | 0 |
| Cycle 1, EOT | 0 |
| Cycle 2, Week 0 | 0 |
| Cycle 2, Week 1 | 1 |
| Cycle 2, Week 2 | 1 |
| Cycle 2, Week 4 | 0 |
| Cycle 2, Week 8 | 1 |
| Cycle 2, Week 12 | 1 |
| Cycle 2, Week 16 | 1 |
| Cycle 2, Week 20 | 0 |
| Cycle 2, Week 24 | 0 |
| Cycle 2, EOT | 0 |
| Cycle 3, Week 0 | 0 |
| Cycle 3, Week 1 | 0 |
| Cycle 3, Week 2 | 0 |
| Cycle 3, EOT | 0 |
| Overall EOT | 1 |
Achieving enteral autonomy is defined as complete weaning off PS. PS (parenteral nutrition or intravenous fluids) was to be considered for managing nutritional support in terms of volume and calories during the treatment period.
| Participants | Teduglutide |
|---|---|
| Cycle 1, Week 1 | 0 |
| Cycle 1, Week 2 | 0 |
| Cycle 1, Week 4 | 0 |
| Cycle 1, Week 8 | 0 |
| Cycle 1, Week 12 | 0 |
| Cycle 1, Week 16 | 0 |
| Cycle 1, Week 20 | 0 |
| Cycle 1, Week 24 | 0 |
| Cycle 1, EOT | 0 |
| Cycle 2, Week 0 | 0 |
| Cycle 2, Week 1 | 0 |
| Cycle 2, Week 2 | 0 |
| Cycle 2, Week 4 | 0 |
| Cycle 2, Week 8 | 0 |
| Cycle 2, Week 12 | 0 |
| Cycle 2, Week 16 | 0 |
| Cycle 2, Week 20 | 0 |
| Cycle 2, Week 24 | 0 |
| Cycle 2, EOT | 0 |
| Cycle 3, Week 0 | 0 |
| Cycle 3, Week 1 | 0 |
| Cycle 3, Week 2 | 0 |
| Cycle 3, EOT | 0 |
| Overall EOT | 0 |
PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume and calories during the treatment period.
| days per week | Teduglutide |
|---|---|
| Cycle 1, Week 1 | 0.0 ± 0.00 |
| Cycle 1, Week 2 | 0.0 ± 0.00 |
| Cycle 1, Week 4 | 0.0 ± 0.00 |
| Cycle 1, Week 8 | 0.0 ± 0.00 |
| Cycle 1, Week 12 | 0.0 ± 0.00 |
| Cycle 1, Week 16 | 0.0 ± 0.00 |
| Cycle 1, Week 20 | 0.0 ± 0.00 |
| Cycle 1, Week 24 | 0.0 ± 0.00 |
| Cycle 1, EOT | 0.0 ± 0.00 |
| Cycle 2, Week 0 | 0.0 ± 0.00 |
| Cycle 2, Week 1 | 0.0 ± 0.00 |
| Cycle 2, Week 2 | 0.0 ± 0.00 |
| Cycle 2, Week 4 | 0.0 ± 0.00 |
| Cycle 2, Week 8 | 0.0 ± 0.00 |
| Cycle 2, Week 12 | 0.0 ± 0.00 |
| Cycle 2, Week 16 | 0.0 ± 0.00 |
| Cycle 2, Week 20 | 0.0 ± 0.00 |
| Cycle 2, Week 24 | 0.0 ± 0.00 |
| Cycle 2, EOT | 0.0 ± 0.00 |
| Cycle 3, Week 0 | 0.0 ± 0.00 |
| Cycle 3, Week 1 | 0.0 ± NA |
| Cycle 3, Week 2 | 0.0 ± NA |
| Cycle 3, EOT | 0.0 ± NA |
| Overall EOT | 0.0 ± 0.00 |
Collected over From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks]). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Teduglutide | 0/3 (0%) | 3/3 (100%) | 3/3 (100%) |
| Event | Teduglutide |
|---|---|
| Device related infectionInfections and infestations | 2/3 |
| BacteraemiaInfections and infestations | 1/3 |
| Catheter site pruritusGeneral disorders | 1/3 |
| Device breakageProduct Issues | 1/3 |
| Vascular device occlusionGeneral disorders | 1/3 |
| Event | Teduglutide |
|---|---|
| COVID-19Infections and infestations | 2/3 |
| EnterocolitisGastrointestinal disorders | 2/3 |
| Respiratory syncytial virus infectionInfections and infestations | 2/3 |
| Blood iron increasedInvestigations | 1/3 |
| Catheter site rashGeneral disorders | 1/3 |
| Lactic acidosisMetabolism and nutrition disorders | 1/3 |
| Liver disorderHepatobiliary disorders | 1/3 |
| OliguriaRenal and urinary disorders | 1/3 |
| Parainfluenzae virus infectionInfections and infestations | 1/3 |
| Skin candidaInfections and infestations | 1/3 |
Safety Analysis Set included all participants who received at least 1 dose of study teduglutide.
| Age, Categorical(Participants) | Teduglutide |
|---|---|
| <=18 years | 3 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Teduglutide |
|---|---|
| Female | 2 |
| Male | 1 |
| Ethnicity (NIH/OMB)(Participants) | Teduglutide |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 3 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Teduglutide |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Teduglutide |
|---|---|
| Japan | 3 |
| Height for Age Z-Score at Baseline(Z score) | Teduglutide |
|---|---|
| Mean | -3.060 ± 1.1601 |
| Weight for Age Z-Score at Baseline(Z score) | Teduglutide |
|---|---|
| Mean | -3.017 ± 1.8048 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be reidentified (due to the limited number of study participants/study sites).
Ran from Jan 2022 to primary completion in Sep 2023, 20 months.
Results were first posted in May 2024, 7 months after primary completion.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 20 months is below that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teduglutide